A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Clinical trial NCT07178795 · RECRUITING

Trial details

NCT number: NCT07178795
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-squamous Non-small Cell Lung Cancer

Start date: 2025-09-29
Primary completion: 2027-12-01
Enrollment: 440

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.